BioMarin Pharmaceutical (BMRN) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for BioMarin Pharmaceutical (BMRN) over the last 10 years. The current PE ratio for BioMarin Pharmaceutical as of August 21, 2017 is 0.00.
|Medical||Medical - Biomedical and Genetics||$14.183B||$1.117B|
|BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.|